Results 31 to 40 of about 237,935 (242)

Gray matter atrophy rate as a marker of disease progression in AD [PDF]

open access: yes, 2010
Global gray matter (GM) atrophy rates were quantified from magnetic resonance imaging (MRI) over 6- and 12-month intervals in 37 patients with Alzheimer's disease (AD) and 19 controls using: (1) nonlinear registration and integration of Jacobian values ...
Miller, David H.   +29 more
core   +1 more source

FAS-dependent cell death in α-synuclein transgenic oligodendrocyte models of multiple system atrophy [PDF]

open access: yes, 2013
Multiple system atrophy is a parkinsonian neurodegenerative disorder. It is cytopathologically characterized by accumulation of the protein p25α in cell bodies of oligodendrocytes followed by accumulation of aggregated α-synuclein in so-called glial ...
Christine L Kragh   +52 more
core   +2 more sources

The efficacy of vaginal clindamycin for the treatment of abnormal genital tract flora in pregnancy. [PDF]

open access: yes, 2003
To assess the efficacy of 2% clindamycin vaginal cream (CVC) to treat bacterial vaginosis (BV) in ...
Sheehan, M   +4 more
core   +1 more source

Hyaluronic Acid and Radiofrequency in Patients with Urogenital Atrophy and Vaginal Laxity

open access: yesPharmaceuticals, 2022
Vaginal laxity (VL) and genitourinary syndrome of menopause (GSM), as well as aesthetic changes in the vulvar skin, often occur together and cause physical, psychological, and functional problems for women and their partners.
Piotr Kolczewski   +10 more
doaj   +1 more source

A Comparison of Dequalinium Chloride Vaginal Tablets (Fluomizin (R)) and Clindamycin Vaginal Cream in the Treatment of Bacterial Vaginosis: A Single-Blind, Randomized Clinical Trial of Efficacy and Safety [PDF]

open access: yes, 2012
Aims: To investigate if vaginal application of dequalinium chloride (DQC, Fluomizin (R)) is as effective as vaginal clindamycin (CLM) in the treatment of bacterial vaginosis (BV).
Gerber, Stefan   +14 more
core   +1 more source

Efficacy of low-dose vaginal 17β-estradiol versus vaginal promestriene for vulvovaginal atrophy

open access: yes, 2021
Vulvovaginal atrophy is frequent, can be bothersome and can impair quality of life in postmenopausal women. The main objective of this prospective, randomized study was to compare the acceptability of low-dose vaginal 17β-estradiol (estradiol) tablets ...
S. Palacios (810500)   +2 more
core   +1 more source

Vaginal atrophy in obstetrician-gynecologist practice [PDF]

open access: yesГинекология, 2014
Vaginal atrophy is a characteristic symptom of menopause, which can develop in young women as a result of temporary or permanent deficiency of estrogen, as well as after operations of the cervix or connective tissue diseases.
I G Shestakova
doaj  

Early Clinical, Imaging, and Pathological Characteristics of SRPK3/TTN‐Digenic Myopathy

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective SRPK3/TTN‐digenic myopathy was recently established as a skeletal muscle myopathy caused by digenic inheritance. This study characterizes the early clinical presentation of SRPK3/TTN‐digenic myopathy in one previously reported and seven newly identified pediatric patients.
Rotem Orbach   +23 more
wiley   +1 more source

The ewe as an animal model of vaginal atrophy and vaginal Er:YAG laser application. [PDF]

open access: yes, 2020
peer reviewedOBJECTIVE: In sheep of reproductive age, we aimed to document decrease in epithelial thickness, glycogen amount, and other vaginal changes after castration and the effect of Er:YAG laser as used clinically.
Hympanova, Lucie   +11 more
core   +1 more source

Effect of Vitamin D on the Proliferation and Barrier of Atrophic Vaginal Epithelial Cells

open access: yesMolecules, 2023
Atrophic vaginitis is very common in postmenopausal women due to declining estrogen levels. Vitamin D plays an important role in promoting epithelial cell proliferation, migration and adhesion.
Dandan Li   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy